Hormonal contraceptives and gynecological cancer risk: clear summary of the latest evidence
What this analysis found, in brief
Contrary to circulating alarmist claims, long-term use of hormonal contraceptives (oral birth control pills) is associated with a reduced risk of certain gynecological cancers—specifically ovarian and endometrial cancer—while showing no overall increase in breast or colorectal cancer risk across most studied lifestyle groups. These conclusions are drawn from a large, population-based cohort study conducted in the United States and reported in 2018 by medichelpline.
Details of the study and its design
Who was studied and what was measured
The investigation enrolled more than 100,000 women and examined associations between duration of oral contraceptive use and the subsequent risk of four cancer types: ovarian, endometrial, breast, and colorectal. Researchers additionally evaluated whether lifestyle factors—smoking status, body weight (obesity), and exercise frequency—modified those associations.
Primary outcomes observed
– Ovarian cancer: Increased duration of oral contraceptive use was linked with a lower risk of ovarian cancer. This protective pattern remained generally consistent across the different lifestyle groups assessed.
– Endometrial cancer: Oral contraceptive use was also associated with a reduced risk of endometrial cancer. The magnitude of risk reduction was most pronounced among current smokers, women classified as obese, and women who reported infrequent exercise.
– Breast and colorectal cancer: The study reported no meaningful association between oral contraceptive use and breast cancer or colorectal cancer risk. This lack of association persisted across the various lifestyle categories evaluated.
How lifestyle factors influenced the findings
Consistency across health behaviors
A notable strength of the analysis is that the protective association for ovarian cancer appeared across smoking, obesity, and exercise subgroups. For endometrial cancer the effect varied more by subgroup but still showed an overall protective trend. For breast and colorectal cancers, the absence of association was consistent across the lifestyle groups examined.
Interpretation of subgroup signals
The stronger endometrial risk reduction observed among smokers, women with obesity, and those who exercised infrequently suggests that oral contraceptive exposure may interact with underlying physiological or hormonal contexts. The study authors emphasize these subgroup differences while also noting that the overall pattern—reduced ovarian and endometrial cancer risk and no clear effect on breast or colorectal cancer—remained the dominant signal.
Study limitations that affect interpretation
Unmeasured mediators and confounding
A primary limitation of the study was the absence of adjustment for certain mediators that could lie on causal paths between oral contraceptive use and cancer outcomes. One example is parity (the number of times a woman has given birth). Because parity can influence both contraceptive choices and gynecological cancer risk, not adjusting for such factors limits the ability to apply mediation methods that better isolate direct versus indirect effects. The authors acknowledge this constraint and note it prevented the use of techniques that provide more refined control for potential confounders.
Unknown contraceptive formulations
Investigators did not obtain detailed information on the specific formulations of the oral contraceptives used by participants. The women in this cohort were likely to have used first- and second-generation oral contraceptive drugs—those marketed before 1989—which contained higher hormone doses than many formulations available today. Because newer contraceptive preparations differ in hormone content and delivery, the applicability of these results to contemporary contraceptive products requires further study.
Clinical implications and practical takeaways
For clinicians counseling patients
This study adds to an existing body of literature showing that oral contraceptive use can be protective against ovarian and endometrial cancer. Clinicians should consider these data when discussing the risks and benefits of oral contraception with patients. The consistency of the ovarian-cancer protective effect across lifestyle subgroups strengthens the evidence clinicians can communicate, while also acknowledging the study’s limitations—particularly the lack of formulation-specific data and unmeasured mediators such as parity.
For patients considering or currently using oral contraceptives
Patients should be reassured that, within this large cohort, longer duration of oral contraceptive use was associated with lower risks of ovarian and endometrial cancer and showed no overall association with breast or colorectal cancer across examined lifestyle groups. However, because formulations have changed over time and individual risk factors vary, decisions about contraceptive choice remain individualized and should be discussed with a healthcare provider.
What remains unknown and future research needs
Despite supportive findings, the authors emphasize the need for further research that: 1) includes information on modern contraceptive formulations and dosing, 2) adjusts for mediators such as parity using mediation analysis where appropriate, and 3) examines whether the observed protective associations persist with newer generations of oral contraceptives and within diverse contemporary populations. Such work would strengthen causal interpretation and help refine guidance for clinicians and patients.
Reference
Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. medichelpline. 2018.
About the author
Prepared by a pharmacist and medical writer with a Master of Pharmacy (MPharm) degree from Cardiff University, UK. The author has professional experience working as a pharmacist in both hospital and community settings within the NHS and has been engaged in clinical research in anaesthetic and pain management. This background informs a clinically grounded appraisal of the study’s methods, findings, and implications for practice.